首页> 外文期刊>International journal of gynecological cancer: official journal of the International Gynecological Cancer Society >Expression of HER-2eu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathol
【24h】

Expression of HER-2eu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathol

机译:HER-2 / neu,表皮生长因子受体,血管内皮生长因子,环氧合酶-2,雌激素受体和孕激素受体在子宫颈小细胞和大细胞神经内分泌癌中的表达:临床病理

获取原文
获取原文并翻译 | 示例
       

摘要

Abstract. Tangjitgamol S, Ramirez PT, Sun CC, See HT, Jhingran A, Kavanagh JJ, Deavers MT. Expression of HER-2eu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int J Gynecol Cancer 2005;15:646-656. We studied the immunohistochemical expression of HER-2eu, epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), cyclooxygenase-2 (COX-2), estrogen receptor (ER), and progesterone receptor (PR) in uterine cervical small cell and large cell neuroendocrine carcinomas (SCNECs and LCNECs) from 24 patients seen at The University of Texas M.D. Anderson Cancer Center. The objectives were to determine their expression and prognostic role in survival. Twenty-three cases (95.8%) expressed VEGF. The tumors expressing EGFR, HER-2eu, and COX-2 were modest in numbers: eight (33.3%), 10(41.7%), and seven (29.2%), respectively. Only one tumor (4.2%) expressed ER, and only two tumors (8.3%) expressed PR. No significant differences in the expression of these factors were found between SCNECs and LCNECs or between stage I and stage II-III tumors. The median overall survival was 21.1 months (95% confidence interval [CI], 17.2-25.0 months). Only HER-2eu expression was significantly associated with survival. Patients with negative HER-2eu expression tumors had significantly shorter survival than those whose tumors were positive, 14.2 months (95% CI, 10.6-17.7 months) versus 33.1 months (95% CI, 0-76.92 months) (P= 0.03). There was a trend toward worse survival in patients with EGFR expression, but this finding was not significant. The combination of negative HER-2eu expression and positive EGFR expression had the worst impact on survival.
机译:抽象。 Tangjitgamol S,Ramirez PT,Sun CC,请参见HT,Jhingran A,Kavanagh JJ,Deavers MT。 HER-2 / neu,表皮生长因子受体,血管内皮生长因子,环氧合酶-2,雌激素受体和孕激素受体在子宫颈小细胞和大细胞神经内分泌癌中的表达:临床病理和预后研究。 Int J Gynecol Cancer 2005; 15:646-656。我们研究了HER-2 / neu,表皮生长因子受体(EGFR),血管内皮生长因子(VEGF),环氧合酶2(COX-2),雌激素受体(ER)和孕激素受体(PR)的免疫组织化学表达。得克萨斯大学医学部安德森分校的24名患者的子宫宫颈小细胞和大细胞神经内分泌癌(SCNEC和LCNEC)。目的是确定它们在生存中的表达和预后作用。 23例(95.8%)表达VEGF。表达EGFR,HER-2 / neu和COX-2的肿瘤数量不多:分别为8(33.3%),10(41.7%)和7(29.2%)。只有一个肿瘤(4.2%)表达ER,只有两个肿瘤(8.3%)表达PR。在SCNEC和LCNEC之间或I期和II-III期肿瘤之间,这些因子的表达没有发现显着差异。中位总生存期为21.1个月(95%置信区间[CI]为17.2-25.0个月)。仅HER-2 / neu表达与存活显着相关。 HER-2 / neu表达阴性的患者的生存期明显短于阳性的患者,分别为14.2个月(95%CI,10.6-17.7个月)和33.1个月(95%CI,0-76.92个月)(P = 0.03) )。 EGFR表达患者的生存率有恶化的趋势,但这一发现并不重要。 HER-2 / neu阴性表达和EGFR阳性表达的组合对生存的影响最大。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号